Glenmede Investment Management LP Purchases 252,666 Shares of Bristol Myers Squibb Company $BMY

Glenmede Investment Management LP grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 31.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,065,333 shares of the biopharmaceutical company’s stock after acquiring an additional 252,666 shares during the quarter. Glenmede Investment Management LP owned 0.05% of Bristol Myers Squibb worth $48,047,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $38,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $40,000. Finally, Bank of Jackson Hole Trust increased its stake in Bristol Myers Squibb by 352.2% in the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 810 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $59.02 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a 50 day moving average of $58.24 and a 200-day moving average of $51.40. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the company earned $1.67 earnings per share. The firm’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. UBS Group reissued a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.00.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.